安徽自贸试验区合肥片区发布20项举措

Core Viewpoint - The Anhui Provincial Government has introduced a set of 20 specific measures to support the integrated innovation of the biopharmaceutical industry chain in the Hefei area of the China (Anhui) Free Trade Zone, marking the first such initiative since the establishment of the free trade zone [1][2]. Group 1: R&D Focus - The measures emphasize activating innovation capabilities in the R&D phase, including the establishment of a "white list" for imported R&D materials and support for AI integration across the biopharmaceutical industry [2][3]. - Eight specific initiatives are outlined to enhance R&D, such as optimizing the joint regulatory mechanism for special items entering the country and supporting clinical trials in local medical institutions [2]. Group 2: Production Focus - The initiative aims to facilitate project implementation in the production phase, including exploring segmented production trials for biological products and enhancing cooperation with the Boao Lecheng International Medical Tourism Pilot Zone [2][3]. - Three measures are proposed to accelerate the planning and environmental assessment processes for projects [2]. Group 3: Review and Approval Focus - The measures seek to optimize approval services, including supporting the establishment of a drug review and inspection sub-center in Hefei and improving flexible service stations for pharmaceutical innovation [2][3]. Group 4: Application Focus - The initiative promotes product application by supporting the construction of research-oriented wards in top-tier hospitals and encouraging eligible medical institutions to participate in self-developed in vitro diagnostic reagent trials [2][3]. - Seven measures are included to facilitate the short-term practice of qualified medical professionals from Hong Kong, Macau, and Taiwan within the free trade zone [2]. Group 5: Highlights and Innovations - The initiative features a comprehensive reform approach, integrating policies from multiple departments to create a "small ecosystem" from R&D to application, fostering collaboration among universities, research institutions, and healthcare organizations [3][4]. - It emphasizes institutional openness to attract high-level resources and talent, including support for overseas pharmaceutical professionals to work in the free trade zone [3][4]. Group 6: Market Orientation and High-Quality Development - The measures are designed with a market-oriented approach, actively addressing the needs of innovative enterprises to create a conducive innovation environment [4]. - The focus is on high-quality development, promoting the integration of technological and industrial innovation, and supporting clinical research in advanced medical fields [4].